Open access
Aug 2026
Linking early and late endpoints in adjuvant immunotherapy trials: an evaluation of multiple clinical outcomes
Strict-primary analyses did not demonstrate a consistent or precise early-endpoint–OS relationship, andarse later windows and uncertainty in both treatment-effect estimates preclude surrogate validation.
Si-Rui Tang, Hui-Ran Zang, Lin-Han Mao et al.
· The Oncologist · 0 citations